MX2014013449A - Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico. - Google Patents
Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico.Info
- Publication number
- MX2014013449A MX2014013449A MX2014013449A MX2014013449A MX2014013449A MX 2014013449 A MX2014013449 A MX 2014013449A MX 2014013449 A MX2014013449 A MX 2014013449A MX 2014013449 A MX2014013449 A MX 2014013449A MX 2014013449 A MX2014013449 A MX 2014013449A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- chemically modified
- postpartum haemorrhage
- heparan sulphate
- modified heparin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644036P | 2012-05-08 | 2012-05-08 | |
| US201261668150P | 2012-07-05 | 2012-07-05 | |
| PCT/SE2013/050510 WO2013169194A1 (en) | 2012-05-08 | 2013-05-07 | Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013449A true MX2014013449A (es) | 2014-12-08 |
Family
ID=49551063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013449A MX2014013449A (es) | 2012-05-08 | 2013-05-07 | Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150099703A1 (enExample) |
| EP (1) | EP2846810A4 (enExample) |
| JP (1) | JP2015516415A (enExample) |
| CN (1) | CN104284667A (enExample) |
| AU (1) | AU2013260209A1 (enExample) |
| BR (1) | BR112014027712B1 (enExample) |
| CA (1) | CA2868403A1 (enExample) |
| HK (1) | HK1203377A1 (enExample) |
| IL (1) | IL234752A0 (enExample) |
| MX (1) | MX2014013449A (enExample) |
| MY (1) | MY192330A (enExample) |
| NZ (1) | NZ701419A (enExample) |
| RU (1) | RU2014149230A (enExample) |
| SG (1) | SG11201407346WA (enExample) |
| UA (1) | UA117912C2 (enExample) |
| WO (1) | WO2013169194A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220142508A (ko) * | 2020-02-17 | 2022-10-21 | 딜라포 아베 | 자간전증 치료용 타폭시파린 |
| CA3255831A1 (en) | 2022-05-03 | 2023-11-09 | Dilafor Ab | NEW MEDICAL USE OF TAFOXIPARIN |
| EP4272749A1 (en) | 2022-05-03 | 2023-11-08 | Dilafor AB | New medical use of tafoxiparin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993810A (en) * | 1996-03-15 | 1999-11-30 | Lebovitz; Shamir Israel | Method of softening or ripening the cervix of a female mammal using collagenase |
| SE521676C2 (sv) * | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US8071569B2 (en) * | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
| UA21707U (en) * | 2006-12-18 | 2007-03-15 | Valerii Ivanovych Linnikov | Method for preventing and treating thrombophilia in course of gestation and postpartum |
| US8445436B2 (en) * | 2007-12-03 | 2013-05-21 | Florida State University Research Foundation, Inc. | Oxytocin and melatonin compositions and associated methods for inducing labor |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| SMT201800143T1 (it) * | 2011-12-19 | 2018-05-02 | Dilafor Ab | Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico |
| US20150045322A1 (en) * | 2012-03-26 | 2015-02-12 | Dilafor Ab | Combination treatment comprising sulphated glycosaminoglycans for inducing labor |
| SG11201406118QA (en) * | 2012-03-26 | 2014-11-27 | Dilafor Ab | Method for treatment of labor arrest |
-
2013
- 2013-05-07 CA CA2868403A patent/CA2868403A1/en not_active Abandoned
- 2013-05-07 US US14/399,450 patent/US20150099703A1/en not_active Abandoned
- 2013-05-07 MY MYPI2014003127A patent/MY192330A/en unknown
- 2013-05-07 MX MX2014013449A patent/MX2014013449A/es unknown
- 2013-05-07 BR BR112014027712-5A patent/BR112014027712B1/pt active IP Right Grant
- 2013-05-07 UA UAA201413096A patent/UA117912C2/uk unknown
- 2013-05-07 EP EP13788384.9A patent/EP2846810A4/en not_active Withdrawn
- 2013-05-07 NZ NZ701419A patent/NZ701419A/en unknown
- 2013-05-07 CN CN201380023470.3A patent/CN104284667A/zh active Pending
- 2013-05-07 WO PCT/SE2013/050510 patent/WO2013169194A1/en not_active Ceased
- 2013-05-07 RU RU2014149230A patent/RU2014149230A/ru not_active Application Discontinuation
- 2013-05-07 JP JP2015511415A patent/JP2015516415A/ja active Pending
- 2013-05-07 SG SG11201407346WA patent/SG11201407346WA/en unknown
- 2013-05-07 HK HK15103952.3A patent/HK1203377A1/xx unknown
- 2013-05-07 AU AU2013260209A patent/AU2013260209A1/en not_active Abandoned
-
2014
- 2014-09-21 IL IL234752A patent/IL234752A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2846810A1 (en) | 2015-03-18 |
| MY192330A (en) | 2022-08-17 |
| BR112014027712A2 (pt) | 2017-06-27 |
| AU2013260209A1 (en) | 2014-11-20 |
| HK1203377A1 (en) | 2015-10-30 |
| IL234752A0 (en) | 2014-11-30 |
| WO2013169194A1 (en) | 2013-11-14 |
| UA117912C2 (uk) | 2018-10-25 |
| SG11201407346WA (en) | 2014-12-30 |
| JP2015516415A (ja) | 2015-06-11 |
| US20150099703A1 (en) | 2015-04-09 |
| CN104284667A (zh) | 2015-01-14 |
| CA2868403A1 (en) | 2013-11-14 |
| EP2846810A4 (en) | 2016-04-13 |
| NZ701419A (en) | 2016-04-29 |
| BR112014027712B1 (pt) | 2023-12-19 |
| RU2014149230A (ru) | 2016-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007410A (es) | Membrana de hidrogel para prevencion de la adhesion. | |
| AR096438A1 (es) | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso | |
| MY185108A (en) | Method for treatment of labor arrest | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| IN2014MN01056A (enExample) | ||
| TN2015000520A1 (en) | Pharmaceutical compositions comprising collagen and sodium hyaluronate | |
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| LT2429515T (lt) | Nauji vaistai, skirti vietiniam naudojimui sulfatuotos hialurono rūgšties, kaip citokinų aktyvumą aktyvuojančio arba inhibuojančio agento, pagrindu | |
| FR2972355B3 (fr) | Melange antimicrobien et revetement pour assister la cicatrisation, ayant un effet antimicrobien | |
| FI3613421T3 (fi) | Asetyylisalisyylihappo tromboembolisen tapahtuman riskin pienentämiseksi | |
| PH12015501045B1 (en) | Bpo wash gel composition | |
| EP3380088A4 (en) | USE OF MICRO-RNA 146A AND NANOCERIA CONJUGATE TO IMPROVE WOUND HEALING AND PROMOTE TISSUE GENERATION | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| MY175743A (en) | Combination treatment comprising sulphated glycosaminoglycans for inducing labor | |
| MX2014013449A (es) | Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico. | |
| PL2983691T3 (pl) | Synergistyczna kombinacja alanino-glutaminy, kwasu hialuronowego i wyciągu z owsa i jej zastosowanie w kompozycji przeznaczonej do zabliźniania ran i naprawiania uszkodzeń skóry | |
| HK1204964A1 (en) | Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote | |
| MX363389B (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| MX2015011418A (es) | Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina. | |
| MX2015009348A (es) | Composiciones hemostaticas. | |
| MX2012012930A (es) | Composicion farmaceutica topica que comprende heparina. | |
| PH12014501044B1 (en) | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells | |
| MX2016013281A (es) | Proteina del factor fviia con vida media extendida para la prevencion y tratamiento de sangrado y regimenes de dosificacion de la misma. | |
| TH152504A (th) | การบำบัดรักษาของภาวะตกเลือดหลังคลอดด้วยเฮปาริน หรือ เฮปารินซัลเฟตที่ถูกดัดแปลงทางเคมี และยากระตุ้นการหดตัวของมดลูก |